Hepatitis B is a major public health problem; it affects over 250 million people worldwide, and 850,000 deaths occur each year as a result of hepatitis B complications. The structure of its etiological agent, the hepatitis B virus (HBV), features a nucleocapsid that is surrounded by a lipid bilayer containing the HBV surface antigen (HBsAg) consiting in three envelope glycoproteins (GPs) designated as small (S), medium (M), and large (L), which are the products of a single open reading frame. They share the C-terminal S domain that contains four putative transmembrane (TM) domains. The L and M proteins have N-terminal extensions (preS1/preS2 and preS2, respectively) that mediate diverse functions in nucleocapsid binding and receptor recognition (Baumert et al., 2014). The first 2- to 75-amino-acid sequence of the preS1 domain of the L protein (Blanchet and Sureau, 2007; Bremer et al., 2011; Le Seyec et al., 1999) and the antigenic loop (AGL) of the S domain (Le Duff et al., 2009; Salisse and Sureau, 2009; Schulze et al., 2007) have been identified as essential determinants for infectivity of HBV and hepatitis delta virus (HDV), a pathogen that depends on HBV GPs for its propagation.

Entry of enveloped viruses into cells can be defined as the sequence of events occurring from the attachment of the virus to the host cell until the release of the genome into the cytoplasm, via fusion between viral and cellular membranes. Like for most enveloped viruses, HBV entry into cells is a finely regulated and complex process consisting of different steps, in which several viral and cellular factors are involved. Its first step involves low-affinity binding to heparan sulfate proteoglycans (HSPGs) residing on the hepatocytes’ surface (Leistner et al., 2008; Schulze et al., 2007). This attachment is mediated by the preS1 region of the L protein and/or the AGL of the S protein (Ni et al., 2014; Schulze et al., 2007). Afterwards, the virus interacts with its high-affinity receptor, the sodium taurocholate-cotransporting polypeptide (NTCP) (Ni et al., 2014; Yan et al., 2012), through the amino-terminal end of the L protein preS1 domain (Glebe et al., 2005; Gripon et al., 2005; Yan et al., 2012). NTCP is an integral membrane protein expressed at the basolateral membrane of hepatocytes, which explains the tropism of HBV for the liver.

The post-binding entry steps of HBV occur through endocytosis; however, the exact mechanism is still unclear and somehow controversial. One early study in HepaRG cells showed that HBV is internalized via caveolin-mediated endocytosis (Macovei et al., 2010). Nevertheless, inhibition of caveolin-mediated endocytosis or silencing of caveolin-1 did not impair HBV infection in tupaia hepatocytes (Bremer et al., 2009) or in HepaG2-NTCP cells (Herrscher et al., 2020). Contrastingly, several other studies presented evidence that HBV endocytosis is clathrin-dependent (Herrscher et al., 2020; Huang et al., 2012; Umetsu et al., 2018). Recent studies have reported that HBV infection of HepaRG cells depends on Rab5 and Rab7 (Macovei et al., 2013), which are GTPases involved in the biogenesis of endosomes, and that the epidermal growth factor receptor (EGFR) is a host-entry cofactor that interacts with NTCP and mediates HBV internalization (Iwamoto et al., 2019). These findings support the hypothesis that HBV is transported from early to mature endosomes. After the early endosome stage, translocation is associated with a gradually decreasing pH, from about 6.2 in early endosomes to close to 5.5 in late endosomes, which allows fusion of many enveloped viruses with the endosomal membrane. However, in the case of HBV, pharmacological agents that raise or neutralize the pH in the endocytic pathway do not affect infection (Macovei et al., 2010; Macovei et al., 2013; Rigg and Schaller, 1992). Furthermore, treatments with protease inhibitors have no effect on infection (Macovei et al., 2013), suggesting that HBV transport into the degradative branch of the endocytic pathway is not required per se to initiate this process.

Virus entry by membrane fusion involves interactions between viral fusion proteins and host receptors, which result in conformational changes of the virus envelope proteins. However, the molecular determinants and mechanism of membrane fusion of HBV remain to be defined. Previous results have indicated the essential role of the cysteine residues of the AGL, as shown by the reduction of virus entry levels by inhibitors of thiol/disulfide exchange reaction (Abou-Jaoudé and Sureau, 2007), hence suggesting a redox state responsible for conformational changes that can have a role during the fusion step.

Here, using a combination of computational and experimental approaches, we sought to better understand how HBV induces the fusion of its lipid membrane with that of the infected cell. Specifically, using a coevolution analysis of HBV GPs and molecular modeling combined with experimental investigations ex vivo in molecular virology and in vivo in liver humanized mice, we provide evidence that the mechanism triggering HBV membrane fusion involves ERp57, a cellular protein disulfide isomerase (PDI). Furthermore, our results highlight the role of specific cysteines in the AGL determinant as well as a sequence (aa 48–66) in the preS1 determinant that could ultimately act as a fusion peptide mediating HBV membrane fusion.

The entry process of enveloped viruses into cells is the series of all events that take place from the attachment of the virus to the host cell until the release of its genome into the cytoplasm. It is a finely regulated and complex process with several steps, in which many viral and cellular factors are involved. The first interaction often occurs with HSPGs. It may lack specificity but serves to give a virus an initial catch hold from which it can recruit specific receptors and entry co-factors that drive the reactions leading to entry. Fusion is the last step of enveloped virus entry and allows the release of the viral capsid into the cytoplasm following the merging of the viral membrane with the membrane of the infected cell. The interactions with the target cell that trigger conformational changes of the viral surface glycoproteins, ultimately leading to the insertion of their fusion peptide into the cell membrane, vary widely for enveloped viruses and can be divided into different scenarios. In the first one (e.g., human immunodeficiency virus), fusion is triggered directly by the interaction of the viral glycoprotein with its cellular receptor, through allosteric conformational rearrangements. In some cases, a sequential interaction with additional host factors is required to trigger the conformational changes required for fusion. In the second scenario (e.g., influenza virus), the interactions with the receptor at the cell surface leads to the endocytosis of viral particles, which is followed by GP protonation in the low-pH environment of the intracellular endosomal organelles that triggers the fusogenic conformational change. In the third scenario (e.g., Ebola virus), the initial interactions of the virion with the cell surface trigger its endocytosis followed by a second interaction with an internal receptor, often found in late endosomes, which is preceded by proteolytic cleavage of the fusion protein by an endosomal protease, leading to fusion activation (Harrison, 2015; White and Whittaker, 2016). Finally, for certain viruses (e.g., Sindbis virus), the fusion protein requires an activating redox reaction involving disulfide bonds of their glycoproteins to induce membrane fusion (Key et al., 2015; Rey and Lok, 2018).

Using a cell-cell fusion assay, we found that HBV fusion activity reached similar levels whether indicator cells expressed or not HSPG and/or NTCP but was not increased when the cell co-cultures were exposed at low pH, in contrast to bona fide pH-dependent GPs such as VSV-G or CCHFV Gn/Gc (Figure 1). That both HSPG and NTCP, which are respectively HBV virion membrane capture molecules (Leistner et al., 2008; Schulze et al., 2007) and specific entry factors (Ni et al., 2014; Yan et al., 2015), are not required for cell-cell fusion highlights that this fusion assay reveals late entry events, such as those occurring after virus interaction with either factor. Similarly, for other viruses such as influenza virus or hepatitis C virus (HCV), binding to their cell entry receptor is not a requirement in both cell-cell fusion (Lin and Cannon, 2002) and liposome fusion (Lavillette et al., 2006) assays triggered by a low-pH treatment. Thus, while it is clear that cell-cell fusion does not recapitulate per se all the events required to promote cell entry of viral particles since it bypasses the step of internalization that subsequently allows membrane fusion in endosomes that are required for entry of the above-mentioned viruses and of HBV (Macovei et al., 2013; Iwamoto et al., 2019), it is a suitable experimental tool for investigating some of the structural and functional determinants that promote envelope glycoprotein membrane-fusion activity (Earp et al., 2004). Accordingly, our results indicate that the trigger for the HBV membrane fusion mechanism not only is independent of an allosteric interaction of its GPs with the NTCP receptor but also is independent of GP protonation that is induced by the low-pH environment of endosomes. That low pH does not increase HBV cell-cell fusion agrees with previous results indicating that pharmacological agents that raise or neutralize the pH of the endocytic pathway had no effect on HBV infection (Macovei et al., 2010; Macovei et al., 2013; Rigg and Schaller, 1992).

Previous results from Abou-Jaoudé and Sureau, 2007 showed that cysteine residues of the HBV antigenic loop are essential for HDV infectivity and that viral entry is blocked by inhibitors of thiol/disulfide exchange reaction. Our results extend this notion as they indicate that such reactions seem to be necessary to mediate a critical early post-binding event but not at a later stage of the infection process since no effect in virus infectivity could be detected when DTNB was added at 4 hr post-infection (Figure 3). Since isomerization of disulfide bonds has been shown to be crucial for conformational rearrangements of GPs from other enveloped viruses leading to fusion (Fenouillet et al., 2007), we sought to investigate if and how such reactions could be implicated during the membrane fusion step of HBV entry. Here, using our cell-cell fusion assay, we found that DTNB blocked HBV GP-mediated membrane fusion (Figure 3B). Altogether, these results indicated a role of disulfide bond network of S GP during HBV membrane fusion.

Capitalizing on the above-mentioned experimental information that inhibitors of thiol/disulfide exchange reactions alter virus entry, we sought to examine how disulfide bonds of the HBV GPs, or rather, how a potential reshuffling of its disulfide bond profile, could be important for HBV entry. Indeed, cross-strand disulfides occurring in some viral surface GPs are believed to play a role in virus entry (Barbouche et al., 2003; Jain et al., 2007; Rosenthal et al., 1998; Wouters et al., 2004). Particularly, allosteric disulfide bonds can modulate the activity of the proteins in which they reside by mediating a structural change when they are reduced or oxidized (Hogg, 2003; Schmidt et al., 2006). Allosteric control of protein function is defined as a change in one site (the allosteric site) that influences another site by exploiting the protein’s flexibility; an allosteric disulfide bond represents the ‘allosteric site’ and the conformational change triggered by cleavage of such bonds alters protein function. For the HBV S protein, we used the contact prediction method RaptorX (Ma et al., 2015; Wang et al., 2017) to predict contacts between four Cys-rich regions of the AGL determinant (Figure 4), which highlighted that two of these regions may likely interact, that is, the Cys-rich regions III and IV (Figure 4—figure supplement 1). Using the secondary structure prediction method JPred (Cole et al., 2008), we proposed that these regions organize in two β-strands and we constructed a three-dimensional model of the region 294–317 of the HBV S GP, which indicated that this sequence is compatible with a β-hairpin structural motif containing a CSD bond between C301 and C310 (Figure 4). Interestingly, the analysis of the signs of the five χ dihedral angles defined by the Cys residues allowed to classify this particular disulfide bond in a -H Staple conformation, which is a particular type of disulfide geometry associated with allosteric functions that is known to trigger conformational changes upon switching between the reduced and oxidized states (Chiu and Hogg, 2019; Schmidt et al., 2006). Hence, we hypothesized that the redox state of the C301-C310 disulfide bond may act as an allosteric switch controlling conformational rearrangements of the HBV GP leading, ultimately, to exposure of the fusion peptide. Of note, the β-hairpin region with the predicted CSD lies at the surface of the S protein according to a three-dimensional in silico model (van Hemert et al., 2008), which may allow interactions with other HBsAg subunits and/or cellular factors. Yet, to test our structural and dynamic model involving a C301-C310 CSD bond in S GP (Figure 4), we reasoned that creating an additional, neighboring disulfide bond between positions 303 and 308 may stabilize the β-hairpin motif (Figure 4), which may prevent molecular rearrangements and, thus, allow membrane fusion to occur. The in silico analysis indicates that the T303C/G308C double mutant most probably generates two structural CSD according to our JPred-based (Cole et al., 2008) structural modeling, which affects the structural conformation of the C301-C310 CSD that is no longer classified as an allosteric bond. When we tested the T303C/G308C mutation in functional assays, we found that the mutant HBV GPs induced an almost complete loss of infection and fusion activity (Figure 5), hence suggesting that by stabilizing cross-strand disulfide exchange, the putative additional disulfide bond prevented conformational rearrangements of HBV GPs that are required for promoting membrane fusion. One possibility is that such stabilization could prevent an isomerization of the C301-C310 CSD bond that generates alternative disulfide bond(s), for example, between C284 and C310, which was proposed in a previous study (Mangold et al., 1995). Yet, the antigenic loss of S induced by these mutations did not allow us to design an assay that would detect the additional disulfide bond in the T303C-G308C mutant nor the block of conformational rearrangements that is suggested by its phenotype.

Assuming that the isomerization of the C301-C310 allosteric CSD or of other thiols/disulfides of the AGL determinant could facilitate the conformational rearrangements of HBV GPs required to promote membrane fusion, we hypothesized that such an isomerization could be induced by a host factor from the PDI family, which are enzymes that can both reduce and oxidize disulfide bonds. PDIs consist of a family of 21 structurally related proteins with a thioredoxin-like domain. Most of these isomerases have a CXXC motif that catalyzes formation, reduction, and rearrangement of the disulfide bonds in proteins (Abell and Brown, 1993). These isomerases are primarily involved in the folding of proteins in the endoplasmic reticulum (ER), catalyzing formation of their disulfide bonds, and most of these isomerases have ER retention signals. However, some isomerases from the PDI family have also been shown to be present at the cell surface, both in functional and in biochemical assays (Turano et al., 2002). Accordingly, cell-surface-localized PDIs are involved in processes such as cell adhesion, nitric oxide signaling, and cell entry of different viruses (Diwaker et al., 2013; Fenouillet et al., 2007). In support of the notion that PDIs are involved in HBV entry, we found that inhibitors that target different PDI members could block infection and cell-cell fusion though not the binding of viral particles to the cell surface. Of note, we found that bacitracin, which targets PDIA1, did not inhibit HBV entry and membrane fusion, in line with a previous study showing that it could not inhibit HDV entry (Abou-Jaoudé and Sureau, 2007). While the above ruled out PDIA1 as an entry co-factor of HBV, we found a strong reduction in the levels of HBV and HDV infection as well as of HBV-induced cell-cell fusion when we used the NTZ and EGCG inhibitors (Figure 6), which target ERp57 (Müller et al., 2008; Pacello et al., 2016). Consistently, we detected a low but significant expression of ERp57 as well as of ERp46 and ERp72 at the cell surface (Figure 7), in agreement with a previous study (Turano et al., 2002). Furthermore, we detected ERp57 in late endosomes (Figure 8), which is meaningful since previous reports have shown that HBV infection of HepaRG cells depends on Rab5 and Rab7 (Macovei et al., 2013), which are GTPases involved in the biogenesis of endosomes, and that the epidermal growth factor receptor is a host-entry cofactor that interacts with NTCP and mediates HBV internalization (Iwamoto et al., 2019). Using a gene silencing approach, we confirmed that down-regulation of ERp57 but not of these alternative PDIs could decrease the levels of HDV and HBV infection as well as of cell-cell fusion (Figure 7). Importantly, we showed that a short-time treatment of liver humanized mice with NTZ could delay HBV infection by approximately 2–4 weeks (Figure 9). Since NTZ has a short half-life of about 1.5 hr in vivo (Ruiz-Olmedo et al., 2017; Stockis et al., 1996) and since NTZ was administrated at very short times before and after HBV inoculation, we calculated that less than 10% of the drug was still present in those mice at 7 hr post-infection, which likely precludes an effect on HBV post-entry steps (Korba et al., 2008). Altogether, these results support the role of ERp57 at early steps of HBV infection and validate this PDI as a therapeutic target. Note that our results did not discard the possibility that some other PDIs could also play a role during HBV entry into cells.

The fusion-mediating GPs of enveloped viruses contain a sequence, termed fusion peptide, that interacts with and destabilizes the cellular target membrane. Such an event is finely controlled so as to occur at the appropriate time and location and to prevent fortuitous inactivation of GP fusion activity and virus infectivity. Hence, a conformational change in these GPs is a requirement to induce the accessibility and function of the fusion peptide segment. Candidate fusion peptides are generally identified as hydrophobic sequences, of approximately 16–26 residues in length, that are conserved within a virus family and that may adopt α-helical conformation with strongly hydrophobic faces. They can be internal or located at the amino-terminus of fusion GP subunits (Apellániz et al., 2014; Epand, 2003; Martin et al., 1999). There are a number of criteria that characterize fusion peptide segments and, while none of these criteria taken individually are absolute to define a fusion peptide segment, they are sufficiently restrictive to predict if a given region of a protein presents features of a fusion peptide segment (Delos and White, 2000; Delos et al., 2000), which needs to be further functionally tested.

Previously, a conserved peptide comprising 23 amino acids at the N-terminal end of the HBV S protein and overlapping its TM1 sequence was shown to interact with model membranes, causing liposome destabilization in a pH-dependent manner (Berting et al., 2000; Rodríguez-Crespo et al., 1994; Rodríguez-Crespo et al., 1995; Rodríguez-Crespo et al., 1999). However, it was also demonstrated that hydrophobic residues in TM1 were critical for S protein expression as well as for infectivity (Siegler and Bruss, 2013). An essential role of TM1 in fusion mechanism, albeit in a pH-independent manner, could be shown for the duck hepatitis B virus (DHBV) (Chojnacki et al., 2005; Grgacic and Schaller, 2000), although there is also evidence for the involvement of the preS domain of DHBV at an early step of infection, likely during the fusion process (Delgado et al., 2012).

Here, through a computational hydropathy analysis of the HBV GPs, we identified two potential short sequences within the preS1 and preS2 regions that may potentially interact with membrane bilayers. To validate these predictions, we characterized in both infection and cell-cell fusion assays HBV GP mutants in key positions in either sequence. We found that while none of the mutations in the preS2 segment altered infection or membrane fusion activities, mutations in the preS1 sequence induced an almost complete loss of infectivity and cell-cell fusion (Figure 2). Note that these mutants had similar if not identical levels of cell-surface-expressed L, M, and S proteins and/or capacity to induce the formation of HDV particles. These results suggested that the preS1 region harbors a fusion peptide in addition to the NTCP-binding determinant.

Overall, our study characterizes some crucial determinants of HBV entry and membrane fusion. The mechanism by which fusion proteins are activated and undergo conformational rearrangements or fusion intermediates is a particularly complex process involving several regions of viral surface GPs. Our results suggest that for HBV, this mechanism could be triggered by ERp57, allowing a thiol/disulfide exchange reaction to occur and regulate isomerization of critical CSD(s), which ultimately results in the exposition of the fusion peptide that seems to be located within the preS1 region.

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for figures 1-3, 5-7 and 9.

1. 1. Abell BA
   2. Brown DT

   (1993) Sindbis virus membrane fusion is mediated by reduction of glycoprotein disulfide bridges at the cell surface

   Journal of Virology 67:5496–5501.

   https://doi.org/10.1128/jvi.67.9.5496-5501.1993

   • PubMed
   • Google Scholar
2. 1. Abou-Jaoudé G
   2. Sureau C

   (2007) Entry of hepatitis Delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange

   Journal of Virology 81:13057–13066.

   https://doi.org/10.1128/JVI.01495-07

   • PubMed
   • Google Scholar
3. 1. Abraham MJ
   2. Murtola T
   3. Schulz R
   4. Páll S
   5. Smith JC
   6. Hess B
   7. Lindahl E

   (2015) GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers

   SoftwareX 1-2:19–25.

   https://doi.org/10.1016/j.softx.2015.06.001

   • Google Scholar
4. 1. Apellániz B
   2. Huarte N
   3. Largo E
   4. Nieva JL

   (2014) The three lives of viral fusion peptides

   Chemistry and Physics of Lipids 181:40–55.

   https://doi.org/10.1016/j.chemphyslip.2014.03.003

   • PubMed
   • Google Scholar
5. 1. Azuma H
   2. Paulk N
   3. Ranade A
   4. Dorrell C
   5. Al-Dhalimy M
   6. Ellis E
   7. Strom S
   8. Kay MA
   9. Finegold M
   10. Grompe M

   (2007) Robust expansion of human hepatocytes in fah−/−/Rag2−/−/Il2rg−/− mice

   Nature Biotechnology 25:903–910.

   https://doi.org/10.1038/nbt1326

   • Google Scholar
6. 1. Barbouche R
   2. Miquelis R
   3. Jones IM
   4. Fenouillet E

   (2003) Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion

   Journal of Biological Chemistry 278:3131–3136.

   https://doi.org/10.1074/jbc.M205467200

   • PubMed
   • Google Scholar
7. 1. Baumert TF
   2. Meredith L
   3. Ni Y
   4. Felmlee DJ
   5. McKeating JA
   6. Urban S

   (2014) Entry of hepatitis B and C viruses - recent progress and future impact

   Current Opinion in Virology 4:58–65.

   https://doi.org/10.1016/j.coviro.2013.12.002

   • PubMed
   • Google Scholar
8. 1. Berman HM
   2. Bhat TN
   3. Bourne PE
   4. Feng Z
   5. Gilliland G
   6. Weissig H
   7. Westbrook J

   (2000) The protein data bank and the challenge of structural genomics

   Nature Structural Biology 7:957–959.

   https://doi.org/10.1038/80734

   • PubMed
   • Google Scholar
9. 1. Berting A
   2. Fischer C
   3. Schaefer S
   4. Garten W
   5. Klenk HD
   6. Gerlich WH

   (2000) Hemifusion activity of a chimeric influenza virus hemagglutinin with a putative fusion peptide from hepatitis B virus

   Virus Research 68:35–49.

   https://doi.org/10.1016/S0168-1702(00)00150-7

   • PubMed
   • Google Scholar
10. 1. Bissig KD
    2. Wieland SF
    3. Tran P
    4. Isogawa M
    5. Le TT
    6. Chisari FV
    7. Verma IM

    (2010) Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment

    Journal of Clinical Investigation 120:924–930.

    https://doi.org/10.1172/JCI40094

    • PubMed
    • Google Scholar
11. 1. Blanchet M
    2. Sureau C

    (2007) Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues

    Journal of Virology 81:5841–5849.

    https://doi.org/10.1128/JVI.00096-07

    • PubMed
    • Google Scholar
12. 1. Bremer CM
    2. Bung C
    3. Kott N
    4. Hardt M
    5. Glebe D

    (2009) Hepatitis B virus infection is dependent on cholesterol in the viral envelope

    Cellular Microbiology 11:249–260.

    https://doi.org/10.1111/j.1462-5822.2008.01250.x

    • PubMed
    • Google Scholar
13. 1. Bremer CM
    2. Sominskaya I
    3. Skrastina D
    4. Pumpens P
    5. El Wahed AA
    6. Beutling U
    7. Frank R
    8. Fritz HJ
    9. Hunsmann G
    10. Gerlich WH
    11. Glebe D

    (2011) N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus

    Journal of Hepatology 55:29–37.

    https://doi.org/10.1016/j.jhep.2010.10.019

    • PubMed
    • Google Scholar
14. 1. Calattini S
    2. Fusil F
    3. Mancip J
    4. Dao Thi VL
    5. Granier C
    6. Gadot N
    7. Scoazec JY
    8. Zeisel MB
    9. Baumert TF
    10. Lavillette D
    11. Dreux M
    12. Cosset FL

    (2015) Functional and biochemical characterization of hepatitis C virus (HCV) Particles produced in a humanized liver mouse model

    Journal of Biological Chemistry 290:23173–23187.

    https://doi.org/10.1074/jbc.M115.662999

    • PubMed
    • Google Scholar
15. 1. Chiu J
    2. Hogg PJ

    (2019) Allosteric disulfides: sophisticated molecular structures enabling flexible protein regulation

    Journal of Biological Chemistry 294:2949–5908.

    https://doi.org/10.1074/jbc.REV118.005604

    • PubMed
    • Google Scholar
16. 1. Chojnacki J
    2. Anderson DA
    3. Grgacic EV

    (2005) A hydrophobic domain in the large envelope protein is essential for fusion of duck hepatitis B virus at the late endosome

    Journal of Virology 79:14945–14955.

    https://doi.org/10.1128/JVI.79.23.14945-14955.2005

    • PubMed
    • Google Scholar
17. 1. Cole C
    2. Barber JD
    3. Barton GJ

    (2008) The jpred 3 secondary structure prediction server

    Nucleic Acids Research 36:W197–W201.

    https://doi.org/10.1093/nar/gkn238

    • PubMed
    • Google Scholar
18. 1. Delgado CL
    2. Núñez E
    3. Yélamos B
    4. Gómez-Gutiérrez J
    5. Peterson DL
    6. Gavilanes F

    (2012) Spectroscopic characterization and fusogenic properties of preS domains of duck hepatitis B virus

    Biochemistry 51:8444–8454.

    https://doi.org/10.1021/bi3008406

    • PubMed
    • Google Scholar
19. 1. Delos SE
    2. Gilbert JM
    3. White JM

    (2000) The central proline of an internal viral fusion peptide serves two important roles

    Journal of Virology 74:1686–1693.

    https://doi.org/10.1128/JVI.74.4.1686-1693.2000

    • PubMed
    • Google Scholar
20. 1. Delos SE
    2. White JM

    (2000) Critical role for the cysteines flanking the internal fusion peptide of avian sarcoma/leukosis virus envelope glycoprotein

    Journal of Virology 74:9738–9741.

    https://doi.org/10.1128/JVI.74.20.9738-9741.2000

    • PubMed
    • Google Scholar
21. 1. Diwaker D
    2. Mishra KP
    3. Ganju L

    (2013)

    Potential roles of protein disulphide isomerase in viral infections

    Acta Virologica 57:293–304.

    • PubMed
    • Google Scholar
22. Book

    1. Earp LJ
    2. Delos SE
    3. Park HE
    4. White JM

    (2004)

    The Many Mechanisms of Viral Membrane Fusion Proteins

    In: Marsh M, editors. Membrane Trafficking in Viral Replication. Berlin Heidelberg: Springer. pp. 25–66.

    • Google Scholar
23. 1. Eklund H
    2. Cambillau C
    3. Sjöberg BM
    4. Holmgren A
    5. Jörnvall H
    6. Höög JO
    7. Brändén CI

    (1984) Conformational and functional similarities between glutaredoxin and thioredoxins

    The EMBO Journal 3:1443–1449.

    https://doi.org/10.1002/j.1460-2075.1984.tb01994.x

    • PubMed
    • Google Scholar
24. 1. Epand RM

    (2003) Fusion peptides and the mechanism of viral fusion

    Biochimica Et Biophysica Acta (BBA) - Biomembranes 1614:116–121.

    https://doi.org/10.1016/S0005-2736(03)00169-X

    • Google Scholar
25. 1. Fenouillet E
    2. Barbouche R
    3. Jones IM

    (2007) Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus

    Antioxidants & Redox Signaling 9:1009–1034.

    https://doi.org/10.1089/ars.2007.1639

    • PubMed
    • Google Scholar
26. 1. Freitas N
    2. Enguehard M
    3. Denolly S
    4. Levy C
    5. Neveu G
    6. Lerolle S
    7. Devignot S
    8. Weber F
    9. Bergeron E
    10. Legros V
    11. Cosset FL

    (2020) The interplays between Crimean-Congo hemorrhagic fever virus (CCHFV) M segment-encoded accessory proteins and structural proteins promote virus assembly and infectivity

    PLOS Pathogens 16:e1008850.

    https://doi.org/10.1371/journal.ppat.1008850

    • PubMed
    • Google Scholar
27. 1. Glebe D
    2. Urban S
    3. Knoop EV
    4. Cag N
    5. Krass P
    6. Grün S
    7. Bulavaite A
    8. Sasnauskas K
    9. Gerlich WH

    (2005) Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and Tupaia hepatocytes

    Gastroenterology 129:234–245.

    https://doi.org/10.1053/j.gastro.2005.03.090

    • PubMed
    • Google Scholar
28. 1. Grgacic EV
    2. Schaller H

    (2000) A metastable form of the large envelope protein of duck hepatitis B virus: low-ph release results in a transition to a hydrophobic, potentially fusogenic conformation

    Journal of Virology 74:5116–5122.

    https://doi.org/10.1128/JVI.74.11.5116-5122.2000

    • PubMed
    • Google Scholar
29. 1. Gripon P
    2. Cannie I
    3. Urban S

    (2005) Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein

    Journal of Virology 79:1613–1622.

    https://doi.org/10.1128/JVI.79.3.1613-1622.2005

    • PubMed
    • Google Scholar
30. 1. Harrison SC

    (2015) Viral membrane fusion

    Virology 479-480:498–507.

    https://doi.org/10.1016/j.virol.2015.03.043

    • Google Scholar
31. 1. Herrscher C
    2. Pastor F
    3. Burlaud-Gaillard J
    4. Dumans A
    5. Seigneuret F
    6. Moreau A
    7. Patient R
    8. Eymieux S
    9. de Rocquigny H
    10. Hourioux C
    11. Roingeard P
    12. Blanchard E

    (2020) Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis

    Cellular Microbiology 22:13205.

    https://doi.org/10.1111/cmi.13205

    • Google Scholar
32. 1. Hogg PJ

    (2003) Disulfide bonds as switches for protein function

    Trends in Biochemical Sciences 28:210–214.

    https://doi.org/10.1016/S0968-0004(03)00057-4

    • PubMed
    • Google Scholar
33. 1. Hogg PJ

    (2013) Targeting allosteric disulphide bonds in Cancer

    Nature Reviews Cancer 13:425–431.

    https://doi.org/10.1038/nrc3519

    • PubMed
    • Google Scholar
34. 1. Huang HC
    2. Chen CC
    3. Chang WC
    4. Tao MH
    5. Huang C

    (2012) Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis

    Journal of Virology 86:9443–9453.

    https://doi.org/10.1128/JVI.00873-12

    • PubMed
    • Google Scholar
35. 1. Huovila AP
    2. Eder AM
    3. Fuller SD

    (1992) Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment

    Journal of Cell Biology 118:1305–1320.

    https://doi.org/10.1083/jcb.118.6.1305

    • PubMed
    • Google Scholar
36. 1. Iwamoto M
    2. Saso W
    3. Sugiyama R
    4. Ishii K
    5. Ohki M
    6. Nagamori S
    7. Suzuki R
    8. Aizaki H
    9. Ryo A
    10. Yun JH
    11. Park SY
    12. Ohtani N
    13. Muramatsu M
    14. Iwami S
    15. Tanaka Y
    16. Sureau C
    17. Wakita T
    18. Watashi K

    (2019) Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization

    PNAS 116:8487–8492.

    https://doi.org/10.1073/pnas.1811064116

    • PubMed
    • Google Scholar
37. 1. Jain S
    2. McGinnes LW
    3. Morrison TG

    (2007) Thiol/disulfide exchange is required for membrane fusion directed by the newcastle disease virus fusion protein

    Journal of Virology 81:2328–2339.

    https://doi.org/10.1128/JVI.01940-06

    • PubMed
    • Google Scholar
38. 1. Key T
    2. Sarker M
    3. de Antueno R
    4. Rainey JK
    5. Duncan R

    (2015) The p10 FAST protein fusion peptide functions as a cystine noose to induce cholesterol-dependent liposome fusion without liposome tubulation

    Biochimica Et Biophysica Acta (BBA) - Biomembranes 1848:408–416.

    https://doi.org/10.1016/j.bbamem.2014.10.020

    • PubMed
    • Google Scholar
39. 1. Komla-Soukha I
    2. Sureau C

    (2006) A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis Delta virus particles

    Journal of Virology 80:4648–4655.

    https://doi.org/10.1128/JVI.80.10.4648-4655.2006

    • PubMed
    • Google Scholar
40. 1. Korba BE
    2. Montero AB
    3. Farrar K
    4. Gaye K
    5. Mukerjee S
    6. Ayers MS
    7. Rossignol JF

    (2008) Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

    Antiviral Research 77:56–63.

    https://doi.org/10.1016/j.antiviral.2007.08.005

    • PubMed
    • Google Scholar
41. 1. Larkin MA
    2. Blackshields G
    3. Brown NP
    4. Chenna R
    5. McGettigan PA
    6. McWilliam H
    7. Valentin F
    8. Wallace IM
    9. Wilm A
    10. Lopez R
    11. Thompson JD
    12. Gibson TJ
    13. Higgins DG

    (2007) Clustal W and clustal X version 2.0

    Bioinformatics 23:2947–2948.

    https://doi.org/10.1093/bioinformatics/btm404

    • PubMed
    • Google Scholar
42. 1. Lavillette D
    2. Bartosch B
    3. Nourrisson D
    4. Verney G
    5. Cosset FL
    6. Penin F
    7. Pécheur EI

    (2006) Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes

    Journal of Biological Chemistry 281:3909–3917.

    https://doi.org/10.1074/jbc.M509747200

    • PubMed
    • Google Scholar
43. 1. Lavillette D
    2. Pécheur EI
    3. Donot P
    4. Fresquet J
    5. Molle J
    6. Corbau R
    7. Dreux M
    8. Penin F
    9. Cosset FL

    (2007) Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus

    Journal of Virology 81:8752–8765.

    https://doi.org/10.1128/JVI.02642-06

    • PubMed
    • Google Scholar
44. 1. Le Duff Y
    2. Blanchet M
    3. Sureau C

    (2009) The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent

    Journal of Virology 83:12443–12451.

    https://doi.org/10.1128/JVI.01594-09

    • PubMed
    • Google Scholar
45. 1. Le Seyec J
    2. Chouteau P
    3. Cannie I
    4. Guguen-Guillouzo C
    5. Gripon P

    (1999) Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain

    Journal of Virology 73:2052–2057.

    https://doi.org/10.1128/JVI.73.3.2052-2057.1999

    • PubMed
    • Google Scholar
46. 1. Leistner CM
    2. Gruen-Bernhard S
    3. Glebe D

    (2008) Role of glycosaminoglycans for binding and infection of hepatitis B virus

    Cellular Microbiology 10:122–133.

    https://doi.org/10.1111/j.1462-5822.2007.01023.x

    • PubMed
    • Google Scholar
47. 1. Lin AH
    2. Cannon PM

    (2002) Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype)

    Virus Research 83:43–56.

    https://doi.org/10.1016/S0168-1702(01)00407-5

    • PubMed
    • Google Scholar
48. 1. Ma J
    2. Wang S
    3. Wang Z
    4. Xu J

    (2015) Protein contact prediction by integrating joint evolutionary coupling analysis and supervised learning

    Bioinformatics 31:3506–3513.

    https://doi.org/10.1093/bioinformatics/btv472

    • PubMed
    • Google Scholar
49. 1. Macovei A
    2. Radulescu C
    3. Lazar C
    4. Petrescu S
    5. Durantel D
    6. Dwek RA
    7. Zitzmann N
    8. Nichita NB

    (2010) Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells

    Journal of Virology 84:243–253.

    https://doi.org/10.1128/JVI.01207-09

    • PubMed
    • Google Scholar
50. 1. Macovei A
    2. Petrareanu C
    3. Lazar C
    4. Florian P
    5. Branza-Nichita N

    (2013) Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment

    Journal of Virology 87:6415–6427.

    https://doi.org/10.1128/JVI.00393-13

    • PubMed
    • Google Scholar
51. 1. Mangold CM
    2. Unckell F
    3. Werr M
    4. Streeck RE

    (1995) Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region

    Virology 211:535–543.

    https://doi.org/10.1006/viro.1995.1435

    • PubMed
    • Google Scholar
52. 1. Marques JR
    2. da Fonseca RR
    3. Drury B
    4. Melo A

    (2010) Conformational characterization of disulfide bonds: a tool for protein classification

    Journal of Theoretical Biology 267:388–395.

    https://doi.org/10.1016/j.jtbi.2010.09.012

    • PubMed
    • Google Scholar
53. 1. Martin I
    2. Ruysschaert J
    3. Epand RM

    (1999) Role of the N-terminal peptides of viral envelope proteins in membrane fusion

    Advanced Drug Delivery Reviews 38:233–255.

    https://doi.org/10.1016/S0169-409X(99)00031-9

    • PubMed
    • Google Scholar
54. 1. Müller J
    2. Naguleswaran A
    3. Müller N
    4. Hemphill A

    (2008) Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides

    Experimental Parasitology 118:80–88.

    https://doi.org/10.1016/j.exppara.2007.06.008

    • PubMed
    • Google Scholar
55. 1. Ni Y
    2. Sonnabend J
    3. Seitz S
    4. Urban S

    (2010) The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly

    Journal of Virology 84:3879–3888.

    https://doi.org/10.1128/JVI.02528-09

    • PubMed
    • Google Scholar
56. 1. Ni Y
    2. Lempp FA
    3. Mehrle S
    4. Nkongolo S
    5. Kaufman C
    6. Fälth M
    7. Stindt J
    8. Königer C
    9. Nassal M
    10. Kubitz R
    11. Sültmann H
    12. Urban S

    (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes

    Gastroenterology 146:1070–1083.

    https://doi.org/10.1053/j.gastro.2013.12.024

    • PubMed
    • Google Scholar
57. 1. Pacello F
    2. D'Orazio M
    3. Battistoni A

    (2016) An ERp57-mediated disulphide exchange promotes the interaction between Burkholderia cenocepacia and epithelial respiratory cells

    Scientific Reports 6:21140.

    https://doi.org/10.1038/srep21140

    • PubMed
    • Google Scholar
58. 1. Perez-Vargas J
    2. Amirache F
    3. Boson B
    4. Mialon C
    5. Freitas N
    6. Sureau C
    7. Fusil F
    8. Cosset F-L

    (2019) Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo

    Nature Communications 10:10117-z.

    https://doi.org/10.1038/s41467-019-10117-z

    • Google Scholar
59. 1. Pettersen EF
    2. Goddard TD
    3. Huang CC
    4. Couch GS
    5. Greenblatt DM
    6. Meng EC
    7. Ferrin TE

    (2004) UCSF chimera--a visualization system for exploratory research and analysis

    Journal of Computational Chemistry 25:1605–1612.

    https://doi.org/10.1002/jcc.20084

    • PubMed
    • Google Scholar
60. 1. Qi Y
    2. Grishin NV

    (2005) Structural classification of thioredoxin-like fold proteins

    Proteins: Structure, Function, and Bioinformatics 58:376–388.

    https://doi.org/10.1002/prot.20329

    • PubMed
    • Google Scholar
61. 1. Ramachandran GN
    2. Ramakrishnan C
    3. Sasisekharan V

    (1963) Stereochemistry of polypeptide chain configurations

    Journal of Molecular Biology 7:95–99.

    https://doi.org/10.1016/S0022-2836(63)80023-6

    • PubMed
    • Google Scholar
62. 1. Rey FA
    2. Lok SM

    (2018) Common features of enveloped viruses and implications for immunogen design for Next-Generation vaccines

    Cell 172:1319–1334.

    https://doi.org/10.1016/j.cell.2018.02.054

    • PubMed
    • Google Scholar
63. 1. Richard C
    2. Liuzzo JP
    3. Moscatelli D

    (1995) Fibroblast growth Factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells

    Journal of Biological Chemistry 270:24188–24196.

    https://doi.org/10.1074/jbc.270.41.24188

    • Google Scholar
64. 1. Rigg RJ
    2. Schaller H

    (1992) Duck hepatitis B virus infection of hepatocytes is not dependent on low pH

    Journal of Virology 66:2829–2836.

    https://doi.org/10.1128/jvi.66.5.2829-2836.1992

    • PubMed
    • Google Scholar
65. 1. Rodríguez-Crespo I
    2. Gómez-Gutiérrez J
    3. Nieto M
    4. Peterson DL
    5. Gavilanes F

    (1994) Prediction of a putative fusion peptide in the S protein of hepatitis B virus

    Journal of General Virology 75:637–639.

    https://doi.org/10.1099/0022-1317-75-3-637

    • PubMed
    • Google Scholar
66. 1. Rodríguez-Crespo I
    2. Núñez E
    3. Gómez-Gutiérrez J
    4. Yélamos B
    5. Albar JP
    6. Peterson DL
    7. Gavilanes F

    (1995) Phospholipid interactions of the putative fusion peptide of hepatitis B virus surface antigen S protein

    Journal of General Virology 76:301–308.

    https://doi.org/10.1099/0022-1317-76-2-301

    • PubMed
    • Google Scholar
67. 1. Rodríguez-Crespo I
    2. Núñez E
    3. Yélamos B
    4. Gómez-Gutiérrez J
    5. Albar JP
    6. Peterson DL
    7. Gavilanes F

    (1999) Fusogenic activity of hepadnavirus peptides corresponding to sequences downstream of the putative cleavage site

    Virology 261:133–142.

    https://doi.org/10.1006/viro.1999.9823

    • PubMed
    • Google Scholar
68. 1. Rosenthal PB
    2. Zhang X
    3. Formanowski F
    4. Fitz W
    5. Wong CH
    6. Meier-Ewert H
    7. Skehel JJ
    8. Wiley DC

    (1998) Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus

    Nature 396:92–96.

    https://doi.org/10.1038/23974

    • PubMed
    • Google Scholar
69. 1. Ruiz-Olmedo MI
    2. González-Hernández I
    3. Palomares-Alonso F
    4. Franco-Pérez J
    5. González F ML
    6. Jung-Cook H

    (2017) Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats

    Saudi Pharmaceutical Journal 25:413–418.

    https://doi.org/10.1016/j.jsps.2016.09.005

    • PubMed
    • Google Scholar
70. 1. Sali A
    2. Blundell TL

    (1993) Comparative protein modelling by satisfaction of spatial restraints

    Journal of Molecular Biology 234:779–815.

    https://doi.org/10.1006/jmbi.1993.1626

    • PubMed
    • Google Scholar
71. 1. Salisse J
    2. Sureau C

    (2009) A function essential to viral entry underlies the hepatitis B virus "a" determinant

    Journal of Virology 83:9321–9328.

    https://doi.org/10.1128/JVI.00678-09

    • PubMed
    • Google Scholar
72. 1. Schmidt B
    2. Ho L
    3. Hogg PJ

    (2006) Allosteric disulfide bonds

    Biochemistry 45:7429–7433.

    https://doi.org/10.1021/bi0603064

    • PubMed
    • Google Scholar
73. 1. Schmidt B
    2. Hogg PJ

    (2007) Search for allosteric disulfide bonds in NMR structures

    BMC Structural Biology 7:49.

    https://doi.org/10.1186/1472-6807-7-49

    • PubMed
    • Google Scholar
74. 1. Schulze A
    2. Gripon P
    3. Urban S

    (2007) Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans

    Hepatology 46:1759–1768.

    https://doi.org/10.1002/hep.21896

    • PubMed
    • Google Scholar
75. 1. Siegler VD
    2. Bruss V

    (2013) Role of transmembrane domains of hepatitis B virus small surface proteins in subviral-particle biogenesis

    Journal of Virology 87:1491–1496.

    https://doi.org/10.1128/JVI.02500-12

    • PubMed
    • Google Scholar
76. 1. Snider C
    2. Jayasinghe S
    3. Hristova K
    4. White SH

    (2009) MPEx: a tool for exploring membrane proteins

    Protein Science 18:2624–2628.

    https://doi.org/10.1002/pro.256

    • PubMed
    • Google Scholar
77. 1. Stockis A
    2. Deroubaix X
    3. Lins R
    4. Jeanbaptiste B
    5. Calderon P
    6. Rossignol JF

    (1996)

    Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers

    International Journal of Clinical Pharmacology and Therapeutics 34:349–351.

    • PubMed
    • Google Scholar
78. 1. Sureau C
    2. Guerra B
    3. Lee H

    (1994) The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis Delta virus

    Journal of Virology 68:4063–4066.

    https://doi.org/10.1128/jvi.68.6.4063-4066.1994

    • PubMed
    • Google Scholar
79. 1. Sureau C

    (2010) The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model

    Methods in Molecular Biology 640:463–473.

    https://doi.org/10.1007/978-1-60761-688-7_25

    • PubMed
    • Google Scholar
80. 1. Teppa E
    2. Zea DJ
    3. Oteri F
    4. Carbone A

    (2020) COVTree: coevolution in OVerlapped sequences by tree analysis server

    Nucleic Acids Research 48:W558–W565.

    https://doi.org/10.1093/nar/gkaa330

    • PubMed
    • Google Scholar
81. 1. Turano C
    2. Coppari S
    3. Altieri F
    4. Ferraro A

    (2002) Proteins of the PDI family: unpredicted non-ER locations and functions

    Journal of Cellular Physiology 193:154–163.

    https://doi.org/10.1002/jcp.10172

    • PubMed
    • Google Scholar
82. 1. Umetsu T
    2. Inoue J
    3. Kogure T
    4. Kakazu E
    5. Ninomiya M
    6. Iwata T
    7. Takai S
    8. Nakamura T
    9. Sano A
    10. Shimosegawa T

    (2018) Inhibitory effect of silibinin on hepatitis B virus entry

    Biochemistry and Biophysics Reports 14:20–25.

    https://doi.org/10.1016/j.bbrep.2018.03.003

    • PubMed
    • Google Scholar
83. 1. van Hemert FJ
    2. Zaaijer HL
    3. Berkhout B
    4. Lukashov VV

    (2008) Mosaic amino acid conservation in 3D-structures of surface protein and polymerase of hepatitis B virus

    Virology 370:362–372.

    https://doi.org/10.1016/j.virol.2007.08.036

    • PubMed
    • Google Scholar
84. 1. Wang S
    2. Sun S
    3. Li Z
    4. Zhang R
    5. Xu J

    (2017) Accurate de novo prediction of protein contact map by Ultra-Deep learning model

    PLOS Computational Biology 13:e1005324.

    https://doi.org/10.1371/journal.pcbi.1005324

    • PubMed
    • Google Scholar
85. 1. White JM
    2. Whittaker GR

    (2016) Fusion of enveloped viruses in endosomes

    Traffic 17:593–614.

    https://doi.org/10.1111/tra.12389

    • PubMed
    • Google Scholar
86. 1. Wouters MA
    2. Lau KK
    3. Hogg PJ

    (2004) Cross-strand disulphides in cell entry proteins: poised to act

    BioEssays 26:73–79.

    https://doi.org/10.1002/bies.10413

    • PubMed
    • Google Scholar
87. 1. Yan H
    2. Zhong G
    3. Xu G
    4. He W
    5. Jing Z
    6. Gao Z
    7. Huang Y
    8. Qi Y
    9. Peng B
    10. Wang H
    11. Fu L
    12. Song M
    13. Chen P
    14. Gao W
    15. Ren B
    16. Sun Y
    17. Cai T
    18. Feng X
    19. Sui J
    20. Li W

    (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

    eLife 1:e00049.

    https://doi.org/10.7554/eLife.00049

    • PubMed
    • Google Scholar
88. 1. Yan H
    2. Liu Y
    3. Sui J
    4. Li W

    (2015) NTCP opens the door for hepatitis B virus infection

    Antiviral Research 121:24–30.

    https://doi.org/10.1016/j.antiviral.2015.06.002

    • PubMed
    • Google Scholar
89. 1. Zhou B
    2. Baldus IB
    3. Li W
    4. Edwards SA
    5. Gräter F

    (2014) Identification of allosteric disulfides from prestress analysis

    Biophysical Journal 107:672–681.

    https://doi.org/10.1016/j.bpj.2014.06.025

    • PubMed
    • Google Scholar

Acceptance summary:

Hepatitis B virus (HBV) is an enveloped virus that enters cells by membrane fusion. Though studied extensively, the mechanisms underlying HBV entry/fusion have not been established. Previous work has indicated that low pH does not act as cellular cue for HBV fusion, as is the case for many viruses. This paper describes modelling studies, and supporting experiments, that identify a potential fusion domain and support a fusion mechanism involving disulphide exchange. The work provides crucial insights to the molecular mechanism through which this important virus infects cells.

Decision letter after peer review:

Thank you for submitting your article "A fusion peptide in preS1 and the protein-disulfide isomerase ERp57 are involved in HBV membrane fusion process" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by José Faraldo-Gómez as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but also that additional experiments are required before it can be again considered for publication, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary

Hepatitis B virus (HBV) is an enveloped virus that gains entry to cells by membrane fusion. Though studied extensively, the mechanisms underlying HBV entry/fusion have not been established. Previous work has indicated that low pH appears not to act as cellular cue for HBV fusion, as is the case for many viruses. This paper describes modelling studies, and supporting experiments, that identify a potential fusion domain and support a mechanism involving disulphide exchange in fusion. The work provides crucial insights to the molecular mechanism through which this important virus infects cells.

Essential revisions

The reviewers consider the work is interesting and potentially publishable in eLife; however, they all raise significant concerns that should be addressed. These include:

1) Analysis of the pre-fusion and reorganised disulphides.

2) Information of the location of ERp57 and how this relates to the likely site of fusion.

3) Assessment of the role of HSPGs in fusion.

4) Characterisation of the HDV particles.

5) Quantitation of comment on the cell-cell fusion assay.

The full reviews are provided below. We strongly urge you to consider these carefully and address the points raised either through the inclusion of additional data or modifications to the text of the manuscript.

Reviewer #1:

Using compounds that inhibit PDIs and RNAi, the authors conclude that ERp57 is likely the primary PDI involved in triggering HBV fusion. As the name suggests ERp57 is primarily associated with the ER. Is there evidence of its expression on the cell surface, which would presumably be necessary to support the cell-cell fusion assays used in this study, or in the endocytic pathway? Although there is evidence of some viruses (e.g. polyoma) being able to gain access to the ER following endocytosis, I am not aware this is the case for HBV.

Reviewer #2:

1. The fact that the specific HBV receptor NTCP is not required in the fusion assays is surprising and a potentially important finding. This may indicate that the cell fusion assays show a phenomenon later, after virus entry into vesicles but may also indicate unspecific interactions driven by the HBV surface proteins, exposed in a non-physiological, artificial manner. For proving specificity of the cell fusion assays the authors should control if HSPGs are required.

2. If the exposure of the three HBV surface proteins is sufficient for efficient cell-to-cell fusion, I am wondering why there are no in vivo data, supporting that HBV infected hepatocytes fuse with their surrounding cells, which – according to the data of the manuscript – must not even be hepatocytes. Either this is a rare event or in vivo exposure of the HBV surface proteins is fundamentally different.

3. The additional disulfide bond in mt T301C-G310C should be experimentally shown. The conformational rearrangements mentioned in the manuscript (e.g. p8) should be experimentally verified. This could be achieved e.g. by immune precipitations using mAbs for showing accessibility of the AGL and preS1 exposure. This could be achieved e.g. by immune precipitations using mAbs for showing accessibility of the AGL and preS1 exposure.

4. The manuscript shows a large number of indirect result figures (i.e. normalized to 100% of three experiments), without giving the original data. This includes pictures and quantifications of cell-to-cell fusions (see 2.)

5. Conformational analyses i.e. proper folding of the HBV surface proteins was based on HD virion formation. This was tested by RTqPCR in the supernatant after 0.45-micron filtration up to 9 days post transfection. I see no reason why the PCR should detect HDV RNA encapsidated in HDV particles only, which should be verified e.g. by ultracentrifugation, immunoprecipitation followed by PCR etc.

6. Figure 2I shows that mt G53A, which allows HDV infection similar to wt HDV, exposes practically only LHBs and very little (if at all) SHBs, which is clearly visible in Figure 1C. This implies that despite of the statement that the mutants do not interfere with virion formation, they may have a significant impact on surface protein folding and exposure on the cell surface.

7. When using inhibitors of e.g. protein disulfide isomerases, no toxicity data were shown.

Reviewer #3:

1) E.g. Alkylation of free sulfhydryls and reduction of disulfides could be done with purified virions, the agents dialysed away, and the chemically modified virions could be used for infectivity studies.

2) E.g. non-reducing gels of S or L protein expressing cells could indicate the presence of disulfide bonds. Combined with the use of cysteine mutants the pattern of shifts will indicate formation or absence of disulfides, and allow conclusions on their positioning. Combinations of alkylation, reduction, alkylation with a different agent followed by mass spectrometry may indeed directly show which sulfhydryls are in a disulfide bond or free. This analysis may also be done prior to and post fusion of cells, which may in fact show the isomerization reaction.

3) It would be important to demonstrate where ERp57 functions to allow fusion. Is it at the plasma membrane or within virus-containing endosomes? Do they physically interact? Perhaps an in vitro isomerization assay would increase the confidence that ERp57 can directly act on the viral protein.

Essential revisions

The reviewers consider the work is interesting and potentially publishable in ; however, they all raise significant concerns that should be addressed. These include:

1) Analysis of the pre-fusion and reorganised disulphides.

2) Information of the location of ERp57 and how this relates to the likely site of fusion.

3) Assessment of the role of HSPGs in fusion.

4) Characterisation of the HDV particles.

5) Quantitation of comment on the cell-cell fusion assay.

The full reviews are provided below. We strongly urge you to consider these carefully and address the points raised either through the inclusion of additional data or modifications to the text of the manuscript.

Reviewer #1:

Using compounds that inhibit PDIs and RNAi, the authors conclude that ERp57 is likely the primary PDI involved in triggering HBV fusion. As the name suggests ERp57 is primarily associated with the ER. Is there evidence of its expression on the cell surface, which would presumably be necessary to support the cell-cell fusion assays used in this study, or in the endocytic pathway? Although there is evidence of some viruses (e.g. polyoma) being able to gain access to the ER following endocytosis, I am not aware this is the case for HBV.

We thank this Reviewer for giving us the opportunity to experimentally address this important question. While PDIs are generally abundantly located in the ER, their capacity to traffic beyond the ER in the secretory pathway has been documented and seems to depend both on specific PDI members and cell types. For example, in addition to the ER, ERp57 has been detected at the cell surface as well as in the nucleus, plasma membrane rafts, and cytosol, as discussed in Turano et al. (2002) and references herein. Of note, ERp46, ERp57 and ERp72 were selected in our study because they can be detected at the cell surface. These considerations are now better discussed in the revised version of our manuscript (pages 9-10 and 13-14).

Noteworthy, we have experimentally addressed this important concern in our Huh7 cells-based assays.

First, we show in revised Figure 7A a FACS analysis of Huh7-NTCP cells that reveal a significant albeit low expression of ERp57 at the cell surface, which supports our results of cell-cell fusion.

Furthermore, we also show in a new Figure 8 some immuno-fluorescence images by confocal microscopy analysis of Huh7-NTCP cells stained with antibodies against ERp57 and Rab5 (early endosomes), Rab7 (late endosomes), Rab11 (recycling endosomes) or Lamp1 (lysosomes). The quantifications of these results show that ERp57 can be detected in late endosomes but poorly in the other above-tested locations. We believe that these results are meaningful since previous reports showed that HBV infection of HepaRG cells depends on Rab5 and Rab7 (Macovei et al., 2013), which are GTPases involved in the biogenesis of endosomes, and that the epidermal growth factor receptor (EGFr) is a host-entry cofactor that interacts with NTCP and mediates HBV internalization (Iwamoto et al., 2019).

Altogether, we confirm that in addition to the ER, ERp57 can be found at locations compatible for both cell-cell fusion and cell-free entry by internalization. The Results and Discussion sections have been modified accordingly (pages 9-10, pages 13-14).

Reviewer #2:

1. The fact that the specific HBV receptor NTCP is not required in the fusion assays is surprising and a potentially important finding. This may indicate that the cell fusion assays show a phenomenon later, after virus entry into vesicles but may also indicate unspecific interactions driven by the HBV surface proteins, exposed in a non-physiological, artificial manner. For proving specificity of the cell fusion assays the authors should control if HSPGs are required.

We thank this Reviewer for giving us the opportunity to address this important point. Indeed, we were first surprised by these results, although for other viruses such as e.g., influenza or HCV, binding to their respective cell-free entry receptors is not a requirement for both cell-cell fusion (Lin and Cannon, 2002) and liposome fusion (Lavillette et al., 2006) assays triggered by low pH treatment. Thus, while it is clear that cell-cell fusion does not recapitulate per se all the events required to promote cell entry of viral particles, such an assay bypasses the step of internalization that subsequently allows membrane fusion in endosomes, which are the sites of entry for these abovementioned viruses and as proposed for HBV (Macovei et al., 2013; Iwamoto et al., 2019).

Noteworthy, we have experimentally addressed this important concern further.

First, we show in revised Figure 1B the results of cell-cell fusion assays performed in the presence of an HSPG blocker, i.e. heparin, which was present throughout the co-culture of donor cells (expressing HBV glycoproteins) and acceptor cells (expressing, or not, NTCP). While the applied doses of heparin could prevent cell-free entry, as shown in Schulze et al. (2007), our results indicate that HSPG blocking does not inhibit cell-cell fusion.

Furthermore, we also show in revised Figure 1C the results of cell-cell fusion assays performed with Chinese ovary cells (CHO) donor cells co-cultured with either CHO cells or CHO-pgsB618 cells. While both cell types do not express NTCP, the latter one does not express HSPGs (Richard et al., 1995). Our results indicate that cell-cell fusion could be detected for either cell type to the same extent as for Huh7 cells.

Overall, these results show that HBV cell-cell fusion requires neither NCTP nor HSPG, which is now described page 5.

As for the comment of this Reviewer that our cell-cell fusion results “may also indicate unspecific interactions driven by the HBV surface proteins, exposed in a non-physiological, artificial manner”, we believe first that previous results studies using the above-mentioned enveloped viruses (influenza and HCV as well as e.g., Togaviruses, Flaviviruses, Rhabdoviruses, Bunyaviruses, and Arenaviruses – see Earp et al., 2004) are in line with our results obtained with HBV and, second, that the cell fusion assays indeed reflect a phenomenon at a late stage of entry, after virus binding and transport into vesicles, which becomes receptor-independent. We discuss these aspects in the revised Discussion (page 11).

2. If the exposure of the three HBV surface proteins is sufficient for efficient cell-to-cell fusion, I am wondering why there are no data, supporting that HBV infected hepatocytes fuse with their surrounding cells, which according to the data of the manuscript must not even be hepatocytes. Either this is a rare event or exposure of the HBV surface proteins is fundamentally different.

Indeed, to the best of our knowledge but also in agreement with our IF analysis of livers from HBV-infected huHep mice (Perez-Vargas et al., 2019), there seems to be no data supporting HBV GP mediated cell-cell fusion in vivo. One possibility is that it may be difficult to achieve a sufficient level of GP expression at the cell surface of HBV-infected cells, in contrast to transfected cells as in our cellcell fusion assay. A second possibility is that the expression level and localization of ERp57 could be differentially regulated in vivo vs. in vitro. Note that unlike other enveloped viruses whose GP expression readily fuses neighboring cells and forms multinucleated giant cells (e.g., Measles), cell-cell fusion with HBV GPs may result in syncytia that hardly harbor over two nuclei, which is very difficult to observe in liver slices from in vivo experiments.

3. The additional disulfide bond in mt T301C-G310C should be experimentally shown. The conformational rearrangements mentioned in the manuscript (e.g. p8) should be experimentally verified. This could be achieved e.g. by immune precipitations using mAbs for showing accessibility of the AGL and preS1 exposure. This could be achieved e.g. by immune precipitations using mAbs for showing accessibility of the AGL and preS1 exposure.

We separately address either concern below:

Concerning “The additional disulfide bond in mt T301C-G310C* should be experimentally shown”

As an attempt to demonstrate that the amino acids substitutions T303C and G308C (TG/CC mutant) induce the formation of an extra disulfide, in addition to the predicted cross-strand disulfide (CDS) between cysteines C301 and C310, we first labeled wt or TG/CC GPs with maleimide-containing reagents: 4-acetamido-40-maleimidylstilbene-2,2’-disulfonic acid (AMS) or 2 kDa PEG-maleimide polymer (mPEG) following treatment with TCEP (as disulfide bond reducer). Both alkylating agents, which specifically bind free thiol groups, should induce detectable electrophoretic migration shifts of ~0.5 kDa and 2.2 kDa per free thiol group, respectively, on HBV GPs. Since HBV GP contains 14 cysteine residues, all located in the S domain, the size of TCEP reduced wt GPs should be increased by ~7 kDa after treatment with AMS and by ~31 kDa after labeling with mPEG. Thus, a 1kDa (for AMS) or 4.4kDa (for mPEG) difference is expected between the wt and the TG/CC mutant, which contains 2 additional cysteines. Second, we reasoned that alkylation without prior treatment with TCEP should lead to formation of thioether bonds between AMS or mPEG and potential free thiols. Thus, should T303C and G308C form a disulfide, we would expect no differences in the sizes of AMS- or mPEG-treated protein samples between the wt and TG/CC mutant GPs.

To test either hypothesis, we performed reduction and/or alkylation of protein lysates from cells expressing wt or TG/CC mutant GPs and recovered by TCA/acetone precipitation, prior to SDS-PAGE and Western blot analysis. As shown in Author response image 1, while HBV GPs were readily detectable after β-mercaptoethanol (A) or TCEP (B) reduction, further alkylation of HBV GPs with AMS prevented their recognition by the Murex antibody (B) that targets the AGL of HBsAg. Aiming to circumvent this, we blotted the membranes with an anti-preS1 antibody instead, leading to detection of the L protein only (A). Treatment with AMS increased the HBV envelope protein’s mass of both wt and TG/CC mutant GPs, though the expected 1kDa difference between the wt and the TG/CC mutant was not clear (B). Treatment of HBV GPs with mPEG rendered them undetectable by the two antibodies used (not shown). Likewise, direct treatment of HBV GPs with AMS or mPEG rendered them undetectable in Western blot analysis (not shown), which prevented us to show the additional disulfide bond.

Author response image 1

Download asset Open asset

Concerning “The conformational rearrangements mentioned in the manuscript (e.g. p8) should be experimentally verified”

Previous studies showed that the reactivity of HBV particles to antibodies against HBsAg was dependent on disulfide bonds (Vyas et al., 1972) and that the antigenicity of sub-viral particles carrying AGL cysteine mutations was drastically affected (Mangold et al., 1995). Moreover, the individual contribution of each cysteine of the antigenic loop (AGL) to the production and infectivity of HDV was extensively analyzed (Abou-Jaoudé and Sureau, 2007; Salisse and Sureau, 2009). Using commercial immunoassays that utilize monoclonal antibodies directed to the immunodominant “a” determinant, it was confirmed that mutation of any of the tested AGL cysteines drastically reduced the antigenicity of HDV particles (see Figure 4 from Salisse and Sureau, 2009). Though, the reduced antigenicity and infectivity was not always accompanied by inhibition of HDV assembly and secretion (AbouJaoudé and Sureau, 2007). Nevertheless, the structure of the AGL seemed to be correlated with infectivity, and thus was defined as the second determinant for HBV/HDV cell entry. Importantly, in addition to the cysteines, several non-cysteine residues were recognized as important for both structure and infectivity of the AGL. Yet, neither T140A (corresponding to T303 in our study) nor G145A (corresponding to G308 in our study) were identified as critical for both the structure of AGL and HDV production and infectivity (Salisse and Sureau, 2009). Furthermore, mutations at these positions (T140 and G145) have been detected in naturally occurring replication competent surface antigen variants of HBV. The vaccine escape mutation G145R has a high impact on AGL structure without affecting infectivity. Indeed, the mutation figure from Salisse and Sureau, 2009 (Figure 4). Specific antigenicity and was shown to confer increased infectivity of HDV particles bearing substitutions of serine for cysteine cell-binding capacity via residues or alanine for noncysteine residues in the AGL of HBsAg. interaction with HSPGs.

Altogether, these data indicated a partial correlation between the three-dimensional structure of the AGL inferred by immunoassays, assembly and secretion, and particle attachment and infectivity (Sureau and Salisse, 2013).

On this ground, to address the comment of this Reviewer, we attempted to identify the changes induced by the introduction of T140C (T303C) and G145C (G308C) mutations in the AGL determinant (T303C-G38C mutant). First, we examined HDV particles for antigenicity using the Murex HBsAg version 3 ELISA and a chemiluminescence immunoassay (CLIA) for detection of HBsAg antigen (see Author response table 1 below).

Whereas HDV particles assembled with wt HBV LMS or with S protein only were equally detected by the two ELISA assays, we found disparities regarding the mutant HDV particles. Indeed, as shown in this Table, the CLIA assay failed to detect any of the mutants, although the T140C (T303C) mutant was readily detected by the Murex immunoassay kit. This confirmed that assessment of AGL exposure is strictly dependent on the anti-HBsAg antibodies used in the immunoassay, which can lead to misleading results. These results are unfortunately in agreement with previous studies that demonstrated that amino acid substitutions in the AGL determinant of HBsAg may account for false negative results in immunoassays, independently of the virus load in sera of infected patients, and, as shown in this study, independently of HDV RNA viral load in the supernatants.

Overall, due to antigenic loss of cysteine mutants, the above results did not allow us to design an assay that can detect the additional disulfide bond in the T303C-G308C mutant nor the block of conformational rearrangements that is suggested by the phenotype of this mutant. We hope that this Reviewer understands this severe limitation that precluded to fully address his/her comment. Accordingly, we have introduced a modification in the revised Discussed to convey this point (page 13).

Nevertheless, we showed that the mutant HDV particles bind Huh7 cells as efficiently as HDV assembled with wt HBV LMS (Figure 5A), allowing us to infer that the changes induced by mutations in the antigenic structure of AGL and/or 294-317 epitope do not impair the ability of HDV particles to attach to the cell surface. Furthermore, we recall that we confirmed preS1 exposure on HDV by testing the ability of mutant particles to infect Huh7-NTCP cells. Indeed, the two single cysteine mutants with altered antigenicity were as infectious as HDV particles assembled with wt HBV LMS (Figure 5B).

4. The manuscript shows a large number of indirect result figures (i.e. normalized to 100% of three experiments), without giving the original data. This includes pictures and quantifications of cell-to-cell fusions (see 2.)

The quantification of cell-cell fusion was done by measuring the luciferase activity induced by fusion between the donor and indicator cells, as explained in the Materials and methods. The absolute values of luciferase activity could show some variations between one experiment to another, owing to cell growth differences in the co-cultures. Thus, in order to address the statistical significance of the different experiments, we chose to express the results as percentage of the WT condition at pH7. Yet, we now show in a new Figure 1—figure supplement 1 the crude results of three independent experiments of cell-cell fusion (used to generate Figure 1A) that are expressed as ratio of values to that of transfection with the empty plasmid.

5. Conformational analyses i.e. proper folding of the HBV surface proteins was based on HD virion formation. This was tested by RTqPCR in the supernatant after 0.45-micron filtration up to 9 days post transfection. I see no reason why the PCR should detect HDV RNA encapsidated in HDV particles only, which should be verified e.g. by ultracentrifugation, immunoprecipitation followed by PCR etc.

HDV RNA replication can be simply initiated by transfection of cell lines with cDNA constructs expressing either genomic or antigenomic HDV RNA as long as they encode a functional S-HDAg. Though, for HDV assembly and release to occur, these cells must also co-express the large form of the δ antigen (L-HDAg), which results from an editing event on the virus antigenome, and envelope proteins from the helper virus, i.e., the HBV surface glycoproteins (HBsAgs). Before standardization of RT-qPCR assays for absolute quantification of HDV genomes, virus replication and egress were conventionally assessed by Northern blot analysis with radioactive probes. As demonstrated before by Camille Sureau’s group, HDV RNA cannot be detected by Northern blotting in the supernatants of Huh7 cells co-transfected with pSVL-D3 (replication competent HDV cDNA construct) and a plasmid devoid of the sequences for the HBsAgs (see e.g., Figure 4 in Julithe et al., 2014). Northern blotting has been gradually replaced by RT-PCR assays, which are more sensitive, to quantify HDV replication following infection as well as HDV titers (total physical particles) released from transfected cells or circulating in human sera. A side-by-side comparison of HDV infectivity both by Northern blot and qPCR validated the latter as an accurate and sensitive method to deduce the number of HDV equivalents present in a sample (see e.g., Table 3 in Gudima et al., 2007). Because within the HDV virion there is one copy of the genome that is associated with 70-200 copies of HDAg, the HDV RNA levels correlate with the number of secreted HDV particles. Moreover, since the HDV RNPs require HBsAgs for assembly and egress, HDV titers are commonly determined by qPCR and expressed as genome equivalents (GE) per ml, representing the total number of physical particles.

As depicted in the Author response image 2, the HDV RNA detected in the producer cell supernatant in a transfection assay lacking the sequences for HBsAg (noGP) represents less than 1% of the HDV genome equivalents detected in the supernatants of cells producing HDV particles. This likely corresponds to HDV RNAs released from dead cells, independently of whether the RNA was extracted from crude supernatants or from supernatants that have been concentrated by ultracentrifugation through a

30% sucrose cushion.

Consistently, HBsAgs but also HDAgs were undetectable in the noGP fraction by Western blot, contrasting with detection of both proteins when more that 1E+07 GE of HDV RNA was loaded.

Author response image 2

Download asset Open asset

6. Figure 2I shows that mt G53A, which allows HDV infection similar to wt HDV, exposes practically only LHBs and very little (if at all) SHBs, which is clearly visible in 1C. This implies that despite of the statement that the mutants do not interfere with virion formation, they may have a significant impact on surface protein folding and exposure on the cell surface.

In the repetitions of this experiment, while the results of the specific experiment displayed in the previous version of Figure 2I exhibited a poorer expression of the mutant G53A as compared to WT, the other experiments showed that L, M and S GPs are expressed from mutant G53A at levels similar to the wt. Yet, we had provided the quantification of these experiments in previous version of supplemental figure 4A, which indicated that all mutants in preS1 were expressed at levels similar to WT. We have now introduced this quantitative analysis in the revised Figure 2I, 2J to better convey this notion and we display in revised Figure 2—figure supplement 2 some western blots for illustrations.

7. When using inhibitors of e.g. protein disulfide isomerases, no toxicity data were shown.

We apologize for this omission. The results of toxicity data for all inhibitors are now shown in the new Figure 1—figure supplement 2.

Reviewer #3:

1) E.g. Alkylation of free sulfhydryls and reduction of disulfides could be done with purified virions, the agents dialysed away, and the chemically modified virions could be used for infectivity studies.

In response to this Reviewer’s suggestion, we would like to recall a previous study of Camille Sureau’s group in 2007 that identified the cysteines of the S domain essential for HDV infectivity, all being located in the AGL, and that extensively analyzed the effect of disulfide bond reducing agents (TCEP and DTT) and alkylators (DTNB, AMS, MTSET and M135) on viral entry (Abou-Jaoudé and Sureau, 2007). First, and in support of our findings that the region 294-317 of the LMS sequence contains a cross-strand disulfide (CDS) between C301 and C310 (Figure 4, our manuscript), the authors showed that substitutions of either cysteine had a pronounced inhibitory effect on infectivity (Figure 3). Second, they also analyzed the effect of reducing or alkylating agents on HDV entry. The inhibitors were added at the time of infection (co-inoculation) or added at 1 day post-inoculation (Figure 5, in Abou-Jaoudé and Sureau, 2007). Similar to the results we obtained with the alkylator DTNB (Figure 3 and Figure 3—figure supplement 1, our manuscript), it was clearly demonstrated that HDV infection is inhibited when the drugs are present during the period of virus-cell exposure but have no effect if added after virus entry. Finally, to further address the importance of thiols/disulfide exchange at the surface of HDV and its implication at viral entry, Abou-Jaoudé and Sureau (2007) pre-treated HDV particles with different doses of AMS (alkylator) or TCEP (reducer) prior to infection. Pre-treatment of HDV particles, with either of the inhibitors, caused HDV loss of infectivity (Figure 6, in Abou-Jaoudé and Sureau, 2007). These previous results are in favor of the hypothesis that not all the cysteines are engaged in disulfide bridging and that free-thiol groups are necessary to catalyze disulfide reduction and likely isomerization events of disulfide bonds events during virus entry. Consistent with this view, we showed that stabilizing the loop containing the putative CSD bond inhibited virus entry and fusion (Figure 5, our manuscript).

Hence, we believe that conducting the experiments requested would merely confirm the previous observations described in Abou-Jaoudé and Sureau (2007). Instead, bringing new insights into the mechanism of HBV membrane fusion, we identified ERp57, a member of PDI-family, as a host factor critically involved in triggering HBV fusion and infection.

2) E.g. non-reducing gels of S or L protein expressing cells could indicate the presence of disulfide bonds. Combined with the use of cysteine mutants the pattern of shifts will indicate formation or absence of disulfides, and allow conclusions on their positioning. Combinations of alkylation, reduction, alkylation with a different agent followed by mass spectrometry may indeed directly show which sulfhydryls are in a disulfide bond or free. This analysis may also be done prior to and post fusion of cells, which may in fact show the isomerization reaction.

Assigning disulfide bonds to specific cysteines tends to be difficult if more than one pair of disulfide bonds are present in the protein. Additionally, mutational analysis of single cysteine residues in a compact protein as HBsAg with 14 cysteine amino acids can result in artifacts, since it can lead to formation of new disulfide bonds with other unmatched cysteines that do not occur in the wt HBV GPs. Also, we would like to recall that under non-reducing conditions, a previous study (Gallagher et al., 2017) showed that HBsAg analyzed under non-reducing conditions is only observed at the top of the gel, which precludes detection of small electrophoretic shifts by western blot, and that detection of HBsAg monomers or small oligomers was only possible after reduction with DTT.

Importantly, we would like to stress that alkylation of HBV GPs prevents the recognition of the S domain by antibodies targeting epitopes within this region. We invite this Reviewer to read our response to the comment #3 of Reviewer #2. Briefly, we aimed at experimentally proving that amino acids substitutions T303C and G308C induced the formation of an extra disulfide bond by labeling wt or double mutant cysteine LMS with maleimide-containing reagents, i.e., 4-acetamido-40maleimidylstilbene-2,2’-disulfonic acid (AMS) or 2 kDa PEG-maleimide polymer (mPEG) that specifically bind free thiol groups. While HBV GPs were readily detectable after TCEP treatment, alkylation of HBV GPs with AMS prevented their recognition by the Murex antibody that targets the AGL of HBsAg. To circumvent this, we blotted the membranes with an anti-preS1 antibody instead, leading to detection of the L protein only. Treatment with AMS increased the HBV envelope protein’s mass of both wt and TG/CC mutant, though the 1kDa difference between the wt and the TG/CC mutant was not clear. Treatment of HBV GPs with mPEG rendered them undetectable by the two antibodies used.

3) It would be important to demonstrate where ERp57 functions to allow fusion. Is it at the plasma membrane or within virus-containing endosomes? Do they physically interact? Perhaps an isomerization assay would increase the confidence that ERp57 can directly act on the viral protein.

This point is similar to that of Reviewer #1 and we thank both Reviewers for giving us the opportunity to address experimentally this important question. While PDIs are generally abundantly located in the ER, their capacity to traffic beyond the ER in the secretory pathway has been documented and seems to depend both on specific PDI members and cell types. For example, in addition to the ER, ERp57 has been detected at the cell surface as well as in the nucleus, plasma membrane rafts, and cytosol, as discussed in Turano et al. (2002) and references herein. Of note, ERp46, ERp57 and ERp72 were selected in our study because they can be detected at the cell surface. These considerations are now better discussed in the revised version of our manuscript (pages 9 and 13).

Noteworthy, we have experimentally addressed this important concern in our Huh7 cells-based assays.

First, we show in revised Figure 7A a FACS analysis of Huh7-NTCP cells that reveal a significant albeit low expression of ERp57 at the cell surface, which supports our results of cell-cell fusion.

Furthermore, we also show in a new Figure 8 some immuno-fluorescence images by confocal microscopy analysis of Huh7-NTCP cells stained with antibodies against ERp57 and Rab5 (early endosomes), Rab7 (late endosomes), Rab11 (recycling endosomes) or Lamp1 (lysosomes). The quantifications of these results show that ERp57 can be detected in late endosomes but poorly in the other above-tested locations. We believe that these results are meaningful since previous reports showed that HBV infection of HepaRG cells depends on Rab5 and Rab7 (Macovei et al., 2013), which are GTPases involved in the biogenesis of endosomes, and that the epidermal growth factor receptor (EGFr) is a host-entry cofactor that interacts with NTCP and mediates HBV internalization (Iwamoto et al., 2019).

Altogether, we confirm that in addition to the ER, ERp57 can be found at locations compatible for both cell-cell fusion and cell-free entry by internalization. The Results and Discussion sections have been modified accordingly (pages 9-10, pages 13-14).

Finally, as for the question of the Reviewer of the physical interaction between ERp57 and viral particles, we found no difference for virion binding to the cell surface for either NTZ-blocked ERp57expressing (Figure 6A) or ERp57-silenced cells (data not shown). However, these results do not rule out that virus/ERp57 interaction could be weak or transient or, alternatively, could preferentially occurs in late endosomes, as above suggested.

References:

Abou-Jaoudé, G., and Sureau, C. (2007). Entry of hepatitis δ virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J. Virol. 81, 13057–13066.

Earp, L.J., Delos, S.E., Park, H.E., and White, J.M. (2004). The Many Mechanisms of Viral Membrane Fusion Proteins. In Membrane Trafficking in Viral Replication, M. Marsh, ed. (Berlin, Heidelberg: Springer Berlin Heidelberg), pp. 25–66.

Gallagher JR, Torian U, McCraw DM, Harris AK. (2017). Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform. Virology. 502:176-187.

Gudima S, He Y, Meier A, Chang J, Chen R, Jarnik M, Nicolas E, Bruss V, Taylor J. (2007). Assembly of Hepatitis Δ Virus: Particle Characterization, Including the Ability To Infect Primary Human Hepatocytes. Journal of Virology 81:3608-3617.

Huovila AP, Eder AM, Fuller SD. (1992). Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment. J Cell Biol. 118(6):1305-20.

Iwamoto, M., Saso, W., Sugiyama, R., Ishii, K., Ohki, M., Nagamori, S., Suzuki, R., Aizaki, H., Ryo, A., Yun, J.-H., et al. (2019). Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proceedings of the National Academy of Sciences 116, 8487– 8492.

Jaoudé GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis δ virus. J Virol. 2005;79(16):10460-10466. doi:10.1128/JVI.79.16.1046010466.2005.

Julithe R, Abou-Jaoudé G, Sureau C. (2014). Modification of the Hepatitis B Virus Envelope Protein Glycosylation Pattern Interferes with Secretion of Viral Particles, Infectivity, and Susceptibility to Neutralizing Antibodies. Journal of Virology 88:9049-9059.

Lambert C, Prange R. Dual topology of the hepatitis B virus large envelope protein: determinants influencing post-translational pre-S translocation. J Biol Chem. 2001 Jun 22;276(25):22265-72.

doi: 10.1074/jbc.M100956200. Epub 2001 Apr 11. PMID: 11301328.

Lavillette, D., Bartosch, B., Nourrisson, D., Verney, G., Cosset, F.-L., Penin, F., and Pécheur, E.-I. (2006). Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J. Biol. Chem. 281, 3909–3917.

Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol. 2009 Dec;83(23):12443-51. doi: 10.1128/JVI.01594-09. Epub 2009 Sep 16. PMID: 19759159; PMCID: PMC2786703.

Lin, A.H., and Cannon, P.M. (2002). Use of pseudotyped retroviral vectors to analyze the receptor binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res 83, 43–56.

Macovei, A., Petrareanu, C., Lazar, C., Florian, P., and Branza-Nichita, N. (2013). Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J. Virol. 87, 6415–6427.

Mangold CM, Unckell F, Werr M, Streeck RE. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology. 1995 Aug 20;211(2):535-43. doi: 10.1006/viro.1995.1435. PMID: 7645257.

Perez-Vargas, J., Amirache, F., Boson, B., Mialon, C., Freitas, N., Sureau, C., Fusil, F., and Cosset, F.-L. (2019). Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nature Communications 10.

Richard, C., Liuzzo, J.P., and Moscatelli, D. (1995). Fibroblast Growth Factor-2 Can Mediate Cell Attachment by Linking Receptors and Heparan Sulfate Proteoglycans on Neighboring Cells. Journal of Biological Chemistry 270, 24188–24196.

Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus "a" determinant. J Virol. 2009 Sep;83(18):9321-8. doi: 10.1128/JVI.00678-09. Epub 2009 Jul 1. PMID: 19570861; PMCID: PMC2738268.

Schulze, A., Gripon, P., and Urban, S. (2007). Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46, 1759–1768.

Suffner S, Gerstenberg N, Patra M, Ruibal P, Orabi A, Schindler M, Bruss V. (2018). Domains of the Hepatitis B Virus Small Surface Protein S Mediating Oligomerization. J Virol. 92(11):e02232-17.

Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2013 Mar;57(3):985-94. doi: 10.1002/hep.26125. Epub 2013 Feb 15. PMID: 23161433.

Turano, C., Coppari, S., Altieri, F., and Ferraro, A. (2002). Proteins of the PDI family: unpredicted nonER locations and functions. J. Cell. Physiol. 193, 154–163.

Vyas GN, Rao KR, Ibrahim AB. Australia antigen (hepatitis B antigen): a conformational antigen dependent on disulfide bonds. Science. 1972 Dec 22;178(4067):1300-1. doi: 10.1126/science.178.4067.1300. PMID: 4118259.

Author details

1. Jimena Pérez-Vargas

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing

   Contributed equally with

   Elin Teppa

   Competing interests

   No competing interests declared

2. Elin Teppa

   1. Sorbonne Université, CNRS, IBPS, Laboratoire de Biologie Computationnelle et Quantitative (LCQB) - UMR 7238, Paris, France
   2. Sorbonne Université, Institut des Sciences du Calcul et des Données (ISCD), Paris, France

   Contribution

   Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing

   Contributed equally with

   Jimena Pérez-Vargas

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-0691-9654

3. Fouzia Amirache

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-6453-3717

4. Bertrand Boson

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-1920-5172

5. Rémi Pereira de Oliveira

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-3005-1277

6. Christophe Combet

   Cancer Research Center of Lyon (CRCL), UMR Inserm 1052 - CNRS 5286 - Université Lyon 1 - Centre Léon Bérard, Lyon, France

   Contribution

   Resources, Software

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-7348-3520

7. Anja Böckmann

   Molecular Microbiology and Structural Biochemistry, UMR5086 CNRS-Université Lyon 1, Lyon, France

   Contribution

   Resources, Software

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-8149-7941

8. Floriane Fusil

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

9. Natalia Freitas

   CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

   Contribution

   Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Contributed equally with

   Alessandra Carbone and François-Loïc Cosset

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-8821-561X

10. Alessandra Carbone

    Sorbonne Université, CNRS, IBPS, Laboratoire de Biologie Computationnelle et Quantitative (LCQB) - UMR 7238, Paris, France

    Contribution

    Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Methodology, Writing - original draft

    Contributed equally with

    Natalia Freitas and François-Loïc Cosset

    For correspondence

    Alessandra.Carbone@lip6.fr

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0003-2098-5743

11. François-Loïc Cosset

    CIRI – Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, France

    Contribution

    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Writing - original draft, Project administration, Writing - review and editing

    Contributed equally with

    Natalia Freitas and Alessandra Carbone

    For correspondence

    Francois-Loic.Cosset@ens-lyon.fr

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0001-8842-3726

• 1,558

  Page views

• 282

  Downloads

• 9

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.